[Click eStock] Pharos iBio, Synergy Between AI Drug Development Platform and R&D Capabilities

Leading Investment & Securities stated in a report on the 17th regarding Pharos iBio that "synergy effects between the artificial intelligence (AI) new drug development platform and research and development (R&D) capabilities are expected."

Leading Investment & Securities highlighted the investment points of Pharos iBio as ▲ AI-based new drug development platform Chemiverse, ▲ securing a pipeline focused on rare and intractable disease treatments, and ▲ expected synergy effects between the AI new drug development platform and R&D capabilities.

They have established a total of five pipelines, with three representative pipelines. ▲ PHI-101: Indicated for recurrent ovarian cancer, depending on the data quality of the Phase 1 clinical trial next year, discussions on licensing out (L/O) may be possible if it advances to Phase 2 clinical trials. ▲ PHI-201: Indicated for solid tumors, currently progressing toward global L/O through joint research and licensing agreements with Yuhan Corporation. ▲ PHI-501: Indicated for malignant melanoma, intractable colorectal cancer, and triple-negative breast cancer, aiming for global L/O next year.

Researcher Yuseongman of Leading Investment & Securities analyzed, "Through the AI new drug development platform, development costs and time are reduced, maximizing the productivity and efficiency of R&D," adding, "By applying drug repositioning technology, the material value is also maximized, securing independent AI new drug development platform competitiveness in optimal drug structure proposals and drug repositioning technologies." Recently, Pharos iBio signed a contract to participate in NVIDIA's startup support program ‘Inception,’ and further cooperation is anticipated.

This content was produced with the assistance of AI translation services.